LOGIN  |  REGISTER
Cue Biopharma
Terns Pharmaceuticals

Universal Health Services Announces 2023 First Quarter Financial Results

April 25, 2023 | Last Trade: US$174.80 1.14 0.66
  • Consolidated Results of Operations, As Reported and As Adjusted  – Three-month periods ended March 31, 2023 and 2022:

KING OF PRUSSIA, Pa., April 25, 2023 /PRNewswire/ -- Universal Health Services, Inc. (NYSE: UHS) announced today that its reported net income attributable to UHS was $163.1 million, or $2.28 per diluted share, during the first quarter of 2023, as compared to $153.9 million, or $2.02 per diluted share, during the first quarter of 2022. Net revenues increased by 5.3% to $3.468 billion during the first quarter of 2023, as compared to $3.293 billion during the first quarter of 2022.

As reflected on the Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule"), our adjusted net income attributable to UHS during the first quarter of 2023, was $167.6 million, or $2.34 per diluted share, as compared to $163.5 million, or $2.15 per diluted share, during the first quarter of 2022. 

As reflected on the Supplemental Schedule, included in our reported results were unrealized losses of $4.5 million, or $.06 per diluted share, ($5.8 million pre-tax) during the first quarter of 2023 and $9.5 million, or $.13 per diluted share, ($12.5 million pre-tax) during the first quarter of 2022. These unrealized losses, which are included in "Other (income) expense, net", resulted from decreases in the market value of certain equity securities. 

As calculated on the attached Supplemental Schedule, our earnings before interest, taxes, depreciation & amortization ("EBITDA net of NCI", NCI is net income attributable to noncontrolling interests), was $407.3 million during the first quarter of 2023, as compared to $368.3 million during the first quarter of 2022. Our adjusted earnings before interest, taxes, depreciation & amortization ("Adjusted EBITDA net of NCI"), which excludes the impact of other (income) expense, net, was $421.1 million during the first quarter of 2023, as compared to $379.5 million during the first quarter of 2022.

Acute Care Services – Three-month periods ended March 31, 2023 and 2022:

During the first quarter of 2023, at our acute care hospitals owned during both periods ("same facility basis"), adjusted admissions (adjusted for outpatient activity) increased by 10.5% while adjusted patient days increased by 3.7%, as compared to the first quarter of 2022. At these facilities, during the first quarter of 2023, net revenue per adjusted admission decreased by 7.5% while net revenue per adjusted patient day decreased 1.5%, as compared to the first quarter of 2022. Net revenues generated from our acute care services on a same facility basis increased by 3.5% during the first quarter of 2023, as compared to the first quarter of 2022. 

Behavioral Health Care Services – Three-month periods ended March 31, 2023 and 2022:

During the first quarter of 2023, at our behavioral health care facilities on a same facility basis, adjusted admissions increased by 7.5% while adjusted patient days increased by 4.7%, as compared to the first quarter of 2022. At these facilities, during the first quarter of 2023, net revenue per adjusted admission increased by 2.2% and net revenue per adjusted patient day increased by 5.0%, as compared to the first quarter of 2022. Net revenues generated from our behavioral health care services increased by 9.7% during the first quarter of 2023, as compared to the first quarter of 2022.

Net Cash Provided by Operating Activities and Liquidity:

Net Cash Provided by Operating Activities:

During the three-month period ended March 31, 2023, our net cash provided by operating activities was $291 million as compared to $445 million during the first three months of 2022. The $155 million net decrease in our net cash provided by operating activities was due primarily to an unfavorable change of $183 million in other working capital accounts due primarily to the timing of disbursements for accrued compensation and accounts payable.

Liquidity:

As of March 31, 2023, we had $875 million of aggregate available borrowing capacity pursuant to our $1.2 billion revolving credit facility, net of outstanding borrowings and letters of credit.       

Stock Repurchase Program:

As of December 31, 2022, we had an aggregate remaining repurchase authorization of approximately $947 million pursuant to our stock repurchase program. Pursuant to the terms of our stock repurchase program, shares of our Class B Common Stock may be repurchased, from time to time as conditions allow, on the open market or in negotiated private transactions. During the first quarter of 2023, we have repurchased 650,000 shares at an aggregate cost of approximately $78.7 million (approximately $121 per share) pursuant to the program.  As of March 31, 2023, we had an aggregate available repurchase authorization of approximately $869 million

Conference call information:

We will hold a conference call for investors and analysts at 9:00 a.m. eastern time on April 26, 2023.  A live webcast of the call will be available on our website at www.uhs.com. To participate via telephone, please register in advance at this link

Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call will be available for one full year following the live call.

General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures:

One of the nation's largest and most respected providers of hospital and healthcare services, Universal Health Services, Inc. has built an impressive record of achievement and performance. Growing steadily since our inception into an esteemed Fortune 500 corporation, our annual revenues during 2022 were approximately $13.4 billion. UHS ranked #297 on the Fortune 500; and #391 on Forbes' list of America's Largest Public Companies. UHS was again recognized as one of the World's Most Admired Companies by Fortune.  

Our operating philosophy is as effective today as it was upon the Company's founding in 1979, enabling us to provide compassionate care to our patients and their loved ones.  Our strategy includes building or acquiring high quality hospitals in rapidly growing markets, investing in the people and equipment needed to allow each facility to thrive, and becoming the leading healthcare provider in each community we serve.

Headquartered in King of Prussia, PA, UHS has approximately 93,800 employees and, through its subsidiaries, operates 27 inpatient acute care hospitals, 331 inpatient behavioral health facilities, 40 outpatient facilities and ambulatory care access points, an insurance offering, a physician network and various related services located in 39 states, Washington, D.C., the United Kingdom and Puerto Rico. It acts as the advisor to Universal Health Realty Income Trust, a real estate investment trust (NYSE:UHT).  For additional information visit www.uhs.com.

This press release contains forward-looking statements based on current management expectations.  Numerous factors, including those disclosed herein, those related to the anticipated impact of COVID-19 on our operations and financial results, those related to healthcare industry trends and those detailed in our filings with the Securities and Exchange Commission (as set forth in Item 1A-Risk Factors and in Item 7-Forward-Looking Statements and Risk Factors in our Form 10-K for the year ended December 31, 2022), may cause the results to differ materially from those anticipated in the forward-looking statements.  These statements are subject to risks and uncertainties and therefore actual results may differ materially.  Readers should not place undue reliance on such forward-looking statements which reflect management's view only as of the date hereof.  We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. 

Many of the factors that could affect our future results are beyond our control or ability to predict, including, but not limited to:

  • The nationwide shortage of nurses and other clinical staff and support personnel has been a significant operating issue facing us and other healthcare providers. In some areas, the labor scarcity is putting a strain on our resources and staff, which has required us to utilize higher–cost temporary labor and pay premiums above standard compensation for essential workers. These factors, which had a material unfavorable impact on our results of operations during 2022, could continue to have an unfavorable material impact on our results of operations for the foreseeable future.
  • The impact of the COVID-19 pandemic, which began during the second half of March, 2020, has had a material effect on our operations and financial results since that time. The length and extent of the disruptions caused by the COVID–19 pandemic are currently unknown; however, we expect such disruptions to continue into the future which could materially affect our financial performance.
  • A significant portion of our revenues are derived from federal and state government programs including the Medicare and Medicaid programs. Payments from these programs are subject to statutory and regulatory changes, administrative rulings, interpretations and determinations, requirements for utilization review, and federal and state funding restrictions. Changes to these programs, if adopted, could materially affect program payments which could materially impact our results of operations.
  • The increase in interest rates has substantially increased our borrowings costs and reduced our ability to access the capital markets on favorable terms. Additional increases in interest rates could have a significant unfavorable impact on our future results of operations and the resulting effect on the capital markets could adversely affect our ability to carry out our strategy.

We believe that adjusted net income attributable to UHS, adjusted net income attributable to UHS per diluted share, EBITDA net of NCI and Adjusted EBITDA net of NCI, which are non-GAAP financial measures ("GAAP" is Generally Accepted Accounting Principles in the United States of America), are helpful to our investors as measures of our operating performance. In addition, we believe that, when applicable, comparing and discussing our financial results based on these measures, as calculated, is helpful to our investors since it neutralizes the effect of material items impacting our net income attributable to UHS, such as, changes in the market value of shares of certain equity securities and other potential material items that are nonrecurring or non-operational in nature including, but not limited to, impairments of goodwill and long-lived and intangible assets, reserves for various matters including settlements, legal judgments and lawsuits, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. To obtain a complete understanding of our financial performance these measures should be examined in connection with net income attributable to UHS, as determined in accordance with GAAP, and as presented in the condensed consolidated financial statements and notes thereto in this report or in our other filings with the Securities and Exchange Commission including our Report on Form 10-K for the year ended December 31, 2022. Since the items included or excluded from these measures are significant components in understanding and assessing financial performance under GAAP, these measures should not be considered to be alternatives to net income as a measure of our operating performance or profitability. Since these measures, as presented, are not determined in accordance with GAAP and are thus susceptible to varying calculations, they may not be comparable to other similarly titled measures of other companies. Investors are encouraged to use GAAP measures when evaluating our financial performance.

Universal Health Services, Inc.

Consolidated Statements of Income

(in thousands, except per share amounts)

(unaudited)

    
 

Three months

 

ended March 31,

 

2023

 

2022

    

Net revenues

$3,467,518

 

$3,292,956

    

Operating charges:

   

   Salaries, wages and benefits

1,753,335

 

1,692,270

   Other operating expenses

878,951

 

820,934

   Supplies expense

379,989

 

371,073

   Depreciation and amortization

141,621

 

143,784

   Lease and rental expense

34,922

 

32,038

 

3,188,818

 

3,060,099

    

Income from operations

278,700

 

232,857

    

Interest expense, net

50,876

 

21,673

Other (income) expense, net

13,723

 

11,201

    

Income before income taxes

214,101

 

199,983

    

Provision for income taxes

51,726

 

48,962

    

Net income

162,375

 

151,021

    

Less:  Net income (loss) attributable to

   

noncontrolling interests ("NCI")

(740)

 

(2,892)

    

Net income attributable to UHS

$163,115

 

$153,913

    
    
    
    
    
    

Basic earnings per share attributable to UHS (a)

$2.31

 

$2.05

    

Diluted earnings per share attributable to UHS (a)

$2.28

 

$2.02

    

Universal Health Services, Inc.

Footnotes to Consolidated Statements of Income

(in thousands, except per share amounts)

(unaudited)

    
 

Three months

(a) Earnings per share calculation:

ended March 31,

 

2023

 

2022

Basic and diluted:

   

Net income attributable to UHS

$163,115

 

$153,913

Less: Net income attributable to unvested restricted share grants

(129)

 

(249)

Net income attributable to UHS - basic and diluted

$162,986

 

$153,664

    

Weighted average number of common shares - basic

70,535

 

75,030

    

Basic earnings per share attributable to UHS:

$2.31

 

$2.05

    

Weighted average number of common shares

70,535

 

75,030

Add: Other share equivalents

952

 

1,011

Weighted average number of common shares and equiv. - diluted

71,487

 

76,041

    

Diluted earnings per share attributable to UHS:

$2.28

 

$2.02

    

Universal Health Services, Inc.

Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule")

For the Three Months ended March 31, 2023 and 2022

(in thousands, except per share amounts)

(unaudited)

        
        
        

Calculation of Earnings/Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization
("EBITDA/Adjusted EBITDA net of NCI")

        
 

Three months ended

 

% Net

 

Three months ended

 

% Net

 

March 31, 2023

 

revenues

 

March 31, 2022

 

revenues

        

Net income attributable to UHS

$163,115

   

$153,913

  

   Depreciation and amortization

141,621

   

143,784

  

   Interest expense, net

50,876

   

21,673

  

   Provision for income taxes

51,726

   

48,962

  

EBITDA net of NCI

$407,338

 

11.7 %

 

$368,332

 

11.2 %

        

Other (income) expense, net

13,723

   

11,201

  

Adjusted EBITDA net of NCI

$421,061

 

12.1 %

 

$379,533

 

11.5 %

        

Net revenues

$3,467,518

   

$3,292,956

  
        
        
        
        
        

Calculation of Adjusted Net Income Attributable to UHS

        
 

Three months ended

 

Three months ended

 

March 31, 2023

 

March 31, 2022

   

Per

   

Per

 

Amount

 

Diluted Share

 

Amount

 

Diluted Share

        

Net income attributable to UHS

$163,115

 

$2.28

 

$153,913

 

$2.02

Plus/minus after-tax adjustments:

       

Unrealized loss on equity securities

4,461

 

0.06

 

9,537

 

0.13

Subtotal adjustments

4,461

 

0.06

 

9,537

 

0.13

Adjusted net income attributable to UHS

$167,576

 

$2.34

 

$163,450

 

$2.15

        
        

Universal Health Services, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

       
   

March 31,

  

December 31,

   

2023

  

2022

Assets

      

Current assets:

      

    Cash and cash equivalents

 

$

109,969

 

$

102,818

    Accounts receivable, net

  

2,032,184

  

2,017,722

    Supplies

  

216,236

  

218,517

    Other current assets

  

200,710

  

198,283

          Total current assets

  

2,559,099

  

2,537,340

       

Property and equipment

  

11,251,315

  

11,085,852

Less: accumulated depreciation

  

(5,297,174)

  

(5,167,394)

   

5,954,141

  

5,918,458

       

Other assets:

      

    Goodwill

  

3,913,906

  

3,909,456

    Deferred income taxes

  

90,918

  

68,397

    Right of use assets-operating leases

  

458,189

  

454,650

    Deferred charges

  

5,987

  

6,264

    Other

  

573,719

  

599,623

Total Assets

 

$

13,555,959

 

$

13,494,188

       

Liabilities and Stockholders' Equity

      

Current liabilities:

      

    Current maturities of long-term debt

 

$

96,235

 

$

81,447

    Accounts payable and other liabilities

  

1,636,102

  

1,760,588

    Operating lease liabilities

  

73,189

  

67,776

    Federal and state taxes

  

57,858

  

4,608

          Total current liabilities

  

1,863,384

  

1,914,419

       

Other noncurrent liabilities

  

532,080

  

487,669

Operating lease liabilities noncurrent

  

396,488

  

395,522

Long-term debt

  

4,707,321

  

4,726,533

       

Redeemable noncontrolling interest

  

4,269

  

4,695

       

UHS common stockholders' equity

  

6,012,108

  

5,920,582

Noncontrolling interest

  

40,309

  

44,768

          Total equity

  

6,052,417

  

5,965,350

       

Total Liabilities and Stockholders' Equity

 

$

13,555,959

 

$

13,494,188

       

Universal Health Services, Inc.

Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

 

Three months

  
 

ended March 31,

 

2023

 

2022

    

Cash Flows from Operating Activities:

   

  Net income

$162,375

 

$151,021

  Adjustments to reconcile net income to net

   

cash provided by operating activities:

   

Depreciation & amortization

141,621

 

143,784

(Gain) loss on sale of assets and businesses

(295)

 

1,084

Stock-based compensation expense

20,964

 

19,055

  Changes in assets & liabilities, net of effects from

   

acquisitions and dispositions:

   

   Accounts receivable

(15,723)

 

(15,073)

   Accrued interest

(662)

 

180

   Accrued and deferred income taxes

46,576

 

47,548

   Other working capital accounts

(119,605)

 

63,308

   Medicare accelerated payments and deferred CARES Act and other grants

136

 

250

   Other assets and deferred charges

24,727

 

26,042

   Other

7,030

 

(4,020)

   Accrued insurance expense, net of commercial premiums paid

42,545

 

41,685

   Payments made in settlement of self-insurance claims

(18,936)

 

(29,431)

          Net cash provided by operating activities

290,753

 

445,433

    

Cash Flows from Investing Activities:

   

   Property and equipment additions

(168,752)

 

(200,002)

   Proceeds received from sales of assets and businesses

9,259

 

10,232

   (Outflows) inflows from foreign exchange contracts that hedge our net U.K. investment

(18,818)

 

20,710

   Decrease in capital reserves of commercial insurance subsidiary

0

 

100

          Net cash used in investing activities

(178,311)

 

(168,960)

    

Cash Flows from Financing Activities:

   

   Repayments of long-term debt

(16,489)

 

(11,966)

   Additional borrowings

11,300

 

117,400

   Financing costs

(292)

 

0

   Repurchase of common shares

(85,039)

 

(365,505)

   Dividends paid

(14,214)

 

(14,875)

   Issuance of common stock

2,988

 

3,503

   Profit distributions to noncontrolling interests

(4,145)

 

(5,289)

   Sale of ownership interests from minority members

0

 

(1,307)

          Net cash used in financing activities

(105,891)

 

(278,039)

    

   Effect of exchange rate changes on cash, cash equivalents and restricted cash

1,650

 

(2,232)

Increase (decrease) in cash, cash equivalents and restricted cash

8,201

 

(3,798)

Cash, cash equivalents and restricted cash, beginning of period

200,837

 

178,934

Cash, cash equivalents and restricted cash, end of period

$209,038

 

$175,136

    

Supplemental Disclosures of Cash Flow Information:

   

  Interest paid

$50,279

 

$20,388

    

  Income taxes paid, net of refunds

$2,360

 

$4,423

    

  Noncash purchases of property and equipment

$61,341

 

$90,730

    
    

Universal Health Services, Inc.

Supplemental Statistical Information

(unaudited)

      
      
     

 % Change

     

3 Months ended

Same Facility:

    

3/31/2023

      

Acute Care Hospitals

     

Revenues

    

3.5 %

Adjusted Admissions

    

10.5 %

Adjusted Patient Days

    

3.7 %

Revenue Per Adjusted Admission

    

-7.5 %

Revenue Per Adjusted Patient Day

    

-1.5 %

      

Behavioral Health Hospitals

     

Revenues

    

9.7 %

Adjusted Admissions

    

7.5 %

Adjusted Patient Days

    

4.7 %

Revenue Per Adjusted Admission

    

2.2 %

Revenue Per Adjusted Patient Day

    

5.0 %

      

UHS Consolidated

  

First Quarter Ended

   

3/31/2023

 

3/31/2022

      

Revenues

  

$3,467,518

 

$3,292,956

EBITDA net of NCI

  

$407,338

 

$368,332

EBITDA Margin net of NCI

  

11.7 %

 

11.2 %

Adjusted EBITDA net of NCI

  

$421,061

 

$379,533

Adjusted EBITDA Margin net of NCI

  

12.1 %

 

11.5 %

      

Cash Flow From Operations

  

$290,753

 

$445,433

Days Sales Outstanding

  

53

 

48

Capital Expenditures 

  

$168,752

 

$200,002

      

Debt

  

$4,803,556

 

$4,299,175

UHS' Shareholders Equity

  

$6,012,108

 

$5,867,872

Debt / Total Capitalization

  

44.4 %

 

42.3 %

Debt / EBITDA net of NCI (1)

  

2.94

 

2.32

Debt / Adjusted EBITDA net of NCI (1)

  

2.82

 

2.32

Debt / Cash From Operations (1)

  

5.71

 

3.42

      

(1) Latest 4 quarters.

     
      

Universal Health Services, Inc.

Acute Care Hospital Services

For the Three months ended

March 31, 2023 and 2022

(in thousands)

         
         

Same Facility Basis - Acute Care Hospital Services

        
         
  

Three months ended

 

Three months ended

  

March 31, 2023

 

March 31, 2022

  

Amount

 

% of Net
Revenues

 

Amount

 

% of Net
Revenues

Net revenues

 

$1,889,080

 

100.0 %

 

$1,824,697

 

100.0 %

Operating charges:

        

Salaries, wages and benefits

 

810,553

 

42.9 %

 

811,643

 

44.5 %

Other operating expenses

 

492,400

 

26.1 %

 

434,470

 

23.8 %

Supplies expense

 

316,256

 

16.7 %

 

310,082

 

17.0 %

Depreciation and amortization

 

86,927

 

4.6 %

 

91,764

 

5.0 %

Lease and rental expense

 

23,592

 

1.2 %

 

20,705

 

1.1 %

Subtotal-operating expenses

 

1,729,728

 

91.6 %

 

1,668,664

 

91.4 %

Income from operations

 

159,352

 

8.4 %

 

156,033

 

8.6 %

Interest expense, net

 

(577)

 

(0.0) %

 

638

 

0.0 %

Other (income) expense, net

 

6,213

 

0.3 %

 

201

 

0.0 %

Income before income taxes

 

$153,716

 

8.1 %

 

$155,194

 

8.5 %

         
         
         

All Acute Care Hospital Services

        
         
  

Three months ended

 

Three months ended

  

March 31, 2023

 

March 31, 2022

  

Amount

 

% of Net
Revenues

 

Amount

 

% of Net
Revenues

Net revenues

 

$1,973,532

 

100.0 %

 

$1,912,316

 

100.0 %

Operating charges:

        

Salaries, wages and benefits

 

843,960

 

42.8 %

 

843,906

 

44.1 %

Other operating expenses

 

544,300

 

27.6 %

 

482,078

 

25.2 %

Supplies expense

 

328,060

 

16.6 %

 

321,427

 

16.8 %

Depreciation and amortization

 

93,326

 

4.7 %

 

94,534

 

4.9 %

Lease and rental expense

 

24,154

 

1.2 %

 

20,852

 

1.1 %

Subtotal-operating expenses

 

1,833,800

 

92.9 %

 

1,762,797

 

92.2 %

Income from operations

 

139,732

 

7.1 %

 

149,519

 

7.8 %

Interest expense, net

 

(577)

 

(0.0) %

 

638

 

0.0 %

Other (income) expense, net

 

7,013

 

0.4 %

 

201

 

0.0 %

Income before income taxes

 

$133,296

 

6.8 %

 

$148,680

 

7.8 %

         

We believe that providing our results on a "Same Facility" basis (which is a non-GAAP measure), which includes the operating results for facilities and businesses operated in both the current year and prior year periods, is helpful to our investors as a measure of our operating performance. Our Same Facility results also neutralize (if applicable), the effect of material items that are nonrecurring or non-operational in nature including items such as, but not limited to, reserves for various matters, settlements, legal judgments and lawsuits, cost related to extinguishment of debt, gains/losses on sales of assets and businesses, impairments of long-lived and intangible assets and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. Our Same Facility basis results exclude from net revenues and other operating expenses, provider tax assessments incurred in each period. However, these provider tax assessments are included in net revenues and other operating expenses as reflected in the table under All Acute Care Hospital Services. The provider tax assessments had no impact on the income before income taxes as reflected on the above tables since the amounts offset between net revenues and other operating expenses. To obtain a complete understanding of our financial performance, the Same Facility results should be examined in connection with our net income as determined in accordance with GAAP and as presented herein and the condensed consolidated financial statements and notes thereto as contained in our Form 10-K for the year ended December 31, 2022.

            

The All Acute Care Hospital Services table summarizes the results of operations for all our acute care operations during the periods presented. These amounts include: (i) our acute care results on a same facility basis, as indicated above; (ii) the impact of provider tax assessments which increased net revenues and other operating expenses but had no impact on income before income taxes, and; (iii) certain other amounts including the results of facilities acquired or opened during the last twelve months.

Universal Health Services, Inc.

Behavioral Health Care Services

For the Three months ended

March 31, 2023 and 2022

(in thousands)

         
         

Same Facility - Behavioral Health Care Services

        
         
  

Three months ended

 

Three months ended

  

March 31, 2023

 

March 31, 2022

  

Amount

 

% of Net
Revenues

 

Amount

 

% of Net
Revenues

Net revenues

 

$1,459,719

 

100.0 %

 

$1,330,812

 

100.0 %

Operating charges:

        

Salaries, wages and benefits

 

805,946

 

55.2 %

 

746,160

 

56.1 %

Other operating expenses

 

277,369

 

19.0 %

 

268,548

 

20.2 %

Supplies expense

 

52,330

 

3.6 %

 

49,618

 

3.7 %

Depreciation and amortization

 

45,001

 

3.1 %

 

45,482

 

3.4 %

Lease and rental expense

 

10,582

 

0.7 %

 

10,261

 

0.8 %

Subtotal-operating expenses

 

1,191,228

 

81.6 %

 

1,120,069

 

84.2 %

Income from operations

 

268,491

 

18.4 %

 

210,743

 

15.8 %

Interest expense, net

 

1,078

 

0.1 %

 

1,227

 

0.1 %

Other (income) expense, net

 

(576)

 

(0.0) %

 

(115)

 

(0.0) %

Income before income taxes

 

267,989

 

18.4 %

 

$209,631

 

15.8 %

         
         
         

All Behavioral Health Care Services

        
         
  

Three months ended

 

Three months ended

  

March 31, 2023

 

March 31, 2022

  

Amount

 

% of Net
Revenues

 

Amount

 

% of Net
Revenues

Net revenues

 

$1,490,489

 

100.0 %

 

$1,366,467

 

100.0 %

Operating charges:

        

Salaries, wages and benefits

 

809,786

 

54.3 %

 

753,886

 

55.2 %

Other operating expenses

 

305,232

 

20.5 %

 

298,467

 

21.8 %

Supplies expense

 

52,488

 

3.5 %

 

50,178

 

3.7 %

Depreciation and amortization

 

45,619

 

3.1 %

 

46,079

 

3.4 %

Lease and rental expense

 

10,668

 

0.7 %

 

10,820

 

0.8 %

Subtotal-operating expenses

 

1,223,793

 

82.1 %

 

1,159,430

 

84.8 %

Income from operations

 

266,696

 

17.9 %

 

207,037

 

15.2 %

Interest expense, net

 

1,211

 

0.1 %

 

1,365

 

0.1 %

Other (income) expense, net

 

(871)

 

(0.1) %

 

(115)

 

(0.0) %

Income before income taxes

 

266,356

 

17.9 %

 

$205,787

 

15.1 %

         

We believe that providing our results on a "Same Facility" basis (which is a non-GAAP measure), which includes the operating results for facilities and businesses operated in both the current year and prior year periods, is helpful to our investors as a measure of our operating performance. Our Same Facility results also neutralize (if applicable), the effect of material items that are nonrecurring or non-operational in nature including items such as, but not limited to, reserves for various matters, settlements, legal judgments, lawsuits and reserves established in connection with the government's investigation of our behavioral health care facilities, cost related to extinguishment of debt, gains/losses on sales of assets and businesses, impairments of long-lived and intangible assets and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. Our Same Facility basis results exclude from net revenues and other operating expenses, provider tax assessments incurred in each period. However, these provider tax assessments are included in net revenues and other operating expenses as reflected in the table under All Behavioral Health Care Services. The provider tax assessments had no impact on the income before income taxes as reflected on the above tables since the amounts offset between net revenues and other operating expenses. To obtain a complete understanding of our financial performance, the Same Facility results should be examined in connection with our net income as determined in accordance with GAAP and as presented herein and in the condensed consolidated financial statements and notes thereto as contained in our Form 10-K for the year ended December 31, 2022.

            

The All Behavioral Health Care Services table summarizes the results of operations for all our behavioral health care facilities during the periods presented. These amounts include: (i) our behavioral health results on a same facility basis, as indicated above; (ii) the impact of provider tax assessments which increased net revenues and other operating expenses but had no impact on income before income taxes, and; (iii) certain other amounts including the results of facilities acquired or opened during the last twelve months as well as the results of certain facilities that were closed or restructured during the past year.

Universal Health Services, Inc.

Selected Hospital Statistics

For the Three months ended

March 31, 2023 and 2022

             
             

AS REPORTED:

            
             
             
  

ACUTE

 

BEHAVIORAL HEALTH

  

3/31/23

 

3/31/22

 

%  change

 

3/31/23

 

3/31/22

 

%  change

             

Hospitals owned and leased

 

27

 

27

 

0.0 %

 

331

 

336

 

-1.5 %

Average licensed beds

 

6,798

 

6,749

 

0.7 %

 

24,232

 

24,243

 

0.0 %

Average available beds

 

6,626

 

6,577

 

0.7 %

 

24,132

 

24,143

 

0.0 %

Patient days

 

404,253

 

405,952

 

-0.4 %

 

1,572,571

 

1,506,351

 

4.4 %

Average daily census

 

4,491.7

 

4,510.6

 

-0.4 %

 

17,473.0

 

16,737.2

 

4.4 %

Occupancy-licensed beds

 

66.1 %

 

66.8 %

 

-1.1 %

 

72.1 %

 

69.0 %

 

4.4 %

Occupancy-available beds

 

67.8 %

 

68.6 %

 

-1.2 %

 

72.4 %

 

69.3 %

 

4.4 %

Admissions

 

80,126

 

75,289

 

6.4 %

 

120,560

 

112,433

 

7.2 %

Length of stay

 

5.0

 

5.4

 

-6.4 %

 

13.0

 

13.4

 

-2.6 %

             

Inpatient revenue

 

$11,401,491

 

$10,239,231

 

11.4 %

 

$2,627,990

 

$2,436,474

 

7.9 %

Outpatient revenue

 

7,296,116

 

5,775,539

 

26.3 %

 

272,371

 

257,113

 

5.9 %

Total patient revenue

 

18,697,607

 

16,014,770

 

16.8 %

 

2,900,361

 

2,693,587

 

7.7 %

Other revenue

 

221,993

 

184,481

 

20.3 %

 

65,318

 

66,697

 

-2.1 %

Gross hospital revenue

 

18,919,600

 

16,199,251

 

16.8 %

 

2,965,679

 

2,760,284

 

7.4 %

Total deductions

 

16,946,068

 

14,286,935

 

18.6 %

 

1,475,190

 

1,393,817

 

5.8 %

Net hospital revenue

 

$1,973,532

 

$1,912,316

 

3.2 %

 

$1,490,489

 

$1,366,467

 

9.1 %

             
             

SAME FACILITY:

            
             
  

ACUTE

 

BEHAVIORAL HEALTH

  

3/31/23

 

3/31/22

 

%  change

 

3/31/23

 

3/31/22

 

%  change

             

Hospitals owned and leased

 

26

 

26

 

0.0 %

 

329

 

329

 

0.0 %

Average licensed beds

 

6,452

 

6,467

 

-0.2 %

 

23,986

 

23,887

 

0.4 %

Average available beds

 

6,280

 

6,295

 

-0.2 %

 

23,886

 

23,787

 

0.4 %

Patient days

 

392,589

 

390,258

 

0.6 %

 

1,557,918

 

1,488,843

 

4.6 %

Average daily census

 

4,362.1

 

4,336.2

 

0.6 %

 

17,310.2

 

16,542.7

 

4.6 %

Occupancy-licensed beds

 

67.6 %

 

67.1 %

 

0.8 %

 

72.2 %

 

69.3 %

 

4.2 %

Occupancy-available beds

 

69.5 %

 

68.9 %

 

0.8 %

 

72.5 %

 

69.5 %

 

4.2 %

Admissions

 

77,737

 

72,507

 

7.2 %

 

119,021

 

110,735

 

7.5 %

Length of stay

 

5.1

 

5.4

 

-6.2 %

 

13.1

 

13.4

 

-2.6 %

             
Terns Pharmaceuticals

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page